NCT02171000View on ClinicalTrials.gov

Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

May 31, 2005

Conditions
Healthy
Interventions
DRUG

BIBR 1048 MS

150 mg capsules, b.i.d, 7 days

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY